PRO-FIB
A fragment of the C-terminal end of fibrinopeptide A, enabling non-invasive monitoring of coagulation-driven fibrotic activity in inflammatory and fibrotic conditions.
Key features and values
- Quantifies C-terminal fragments of fibrinopeptide A, reflecting coagulation-related fibrotic activity.
- Provides a non-invasive measure of fibrotic processes associated with coagulation pathways.
- Supports monitoring of disease progression and response to therapies targeting coagulation-induced fibrosis.
- Applicable in research on conditions characterized by aberrant coagulation and fibrosis, such as liver fibrosis and certain cancers.
- Facilitates evaluation of interventions aimed at modulating coagulation-driven fibrotic activity.
- Complements other biomarkers for a comprehensive assessment of fibrotic dynamics.
- Utilized in studies investigating the role of coagulation in fibrotic disease progression.
Description
The PRO-FIB biomarker assay measures specific fragments of the C-terminal end of fibrinopeptide A, serving as an indicator of coagulation-driven fibrotic activity. This non-invasive assay provides insights into fibrotic processes associated with coagulation pathways in various inflammatory and fibrotic conditions. By quantifying fibrinopeptide A fragments, the PRO-FIB assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of coagulation-induced fibrosis. It serves as a valuable tool in research settings for assessing the dynamics of fibrotic activity related to coagulation.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
